Odonate Therapeutics Inc (ODT) Stock Price, Forecast & Analysis

NASDAQ:ODT

1.12
-0.05 (-4.27%)
At close: Jan 14, 2022
1.11
-0.01 (-0.89%)
After Hours: 1/14/2022, 8:44:12 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

ODT Key Statistics, Chart & Performance

Key Statistics
Market Cap43.11M
Revenue(TTM)N/A
Net Income(TTM)-102.07M
Shares38.49M
Float37.79M
52 Week High28.41
52 Week Low0.85
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.68
PEN/A
Fwd PEN/A
Earnings (Next)03-01
IPO2017-12-07
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
ODT short term performance overview.The bars show the price performance of ODT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

ODT long term performance overview.The bars show the price performance of ODT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ODT is 1.12 null. In the past month the price decreased by -21.13%. In the past year, price decreased by -94.4%.

Odonate Therapeutics Inc / ODT Daily stock chart

ODT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ODT Full Technical Analysis Report

ODT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ODT. Both the profitability and financial health of ODT have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ODT Full Fundamental Analysis Report

ODT Financial Highlights

Over the last trailing twelve months ODT reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 31.46% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -96.5%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%60.22%
Sales Q2Q%N/A
EPS 1Y (TTM)31.46%
Revenue 1Y (TTM)N/A
ODT financials

ODT Forecast & Estimates

9 analysts have analysed ODT and the average price target is 4.08 null. This implies a price increase of 264.29% is expected in the next year compared to the current price of 1.12.


Analysts
Analysts46.67
Price Target4.08 (264.29%)
EPS Next Y54.53%
Revenue Next YearN/A
ODT Analyst EstimatesODT Analyst Ratings

ODT Ownership

Ownership
Inst Owners0.06%
Ins Owners20.59%
Short Float %N/A
Short RatioN/A
ODT Ownership

ODT Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO30.65985.228B
JNJ JOHNSON & JOHNSON21.04593.362B
MRK MERCK & CO. INC.22.63307.597B
PFE PFIZER INC9.02154.31B
BMY BRISTOL-MYERS SQUIBB CO10.07125.402B
ZTS ZOETIS INC18.7856.699B
RPRX ROYALTY PHARMA PLC- CL A8.726.207B
VTRS VIATRIS INC6.3618.503B
ELAN ELANCO ANIMAL HEALTH INC25.6713.107B
AXSM AXSOME THERAPEUTICS INC200.528.567B

Related stock screener links

View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About ODT

Company Profile

ODT logo image Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent.

Company Info

Odonate Therapeutics Inc

3 East 28Th Street, 10Th Floor

New York City NEW YORK 10016 US

CEO: Kevin Tang

Employees: 137

ODT Company Website

Phone: 13322060935.0

Odonate Therapeutics Inc / ODT FAQ

Can you describe the business of Odonate Therapeutics Inc?

Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent.


What is the current price of ODT stock?

The current stock price of ODT is 1.12 null. The price decreased by -4.27% in the last trading session.


Does ODT stock pay dividends?

ODT does not pay a dividend.


How is the ChartMill rating for Odonate Therapeutics Inc?

ODT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What sector and industry does Odonate Therapeutics Inc belong to?

Odonate Therapeutics Inc (ODT) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the PE ratio for ODT stock?

Odonate Therapeutics Inc (ODT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.68).


What is the next earnings date for ODT stock?

Odonate Therapeutics Inc (ODT) will report earnings on 2022-03-01, before the market open.